



An improved synthesis of haloacetamide-based inactivators of protein arginine deiminase 4 (PAD4)

Corey P. Causey, Paul R. Thompson *

Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter Street, Columbia, SC 29208, United States

ARTICLE INFO

Article history:

Received 5 March 2008

Revised 1 May 2008

Accepted 5 May 2008

Available online 9 May 2008

ABSTRACT

Protein arginine deiminase 4 (PAD4) is an enzyme that hydrolyzes peptidyl arginine residues to form citrulline and ammonia. This enzyme has been implicated in several disease states, for example, rheumatoid arthritis, and therefore represents a unique target for the development of a novel therapeutic. A solution-phase synthesis of Cl-amidine, the most potent PAD4 inactivator described to date, has been developed. This synthesis proceeds in 80% yield over four steps at a significantly (12-fold) lower cost.

© 2008 Elsevier Ltd. All rights reserved.

Although long considered a relatively minor post-translational modification, protein citrullination (Fig. 1) has recently come to the forefront because this modification appears to be abnormally increased in numerous human diseases, including: multiple sclerosis,¹ Alzheimer's disease,² primary open-angle glaucoma,^{3,4} various adenocarcinomas,⁵ and rheumatoid arthritis (RA).^{6,7} In particular, the links between abnormal protein citrullination and RA are especially strong and a significant body of evidence suggests that the enzymes responsible for this modification, that is, the protein arginine deiminases (PADs), are dysregulated in RA.^{6,7} This evidence includes the fact that mutations within the gene encoding PAD4, a PAD isozyme, are associated with the onset and progression of RA in Japanese, Korean, and Caucasian populations.^{8–11} Additional evidence includes the facts that the levels of PADs 2 and 4 are increased in the RA synovium and RA patients produce autoantibodies that recognize citrulline-containing proteins.^{12–15} The presence of these autoantibodies in patient's sera is highly significant because they can be detected before the onset of overt clinical symptoms and their presence in patient's sera is correlated with a more severe disease course.^{14–16}

The apparent causal relationship between PAD dysregulation and RA disease onset thereby suggested these enzymes as a novel therapeutic target for RA that could overcome the limitations of current therapies, which focus on disease management¹⁷ rather than the treatment of an underlying cause of the disease. Towards that goal, we have recently described the synthesis and characterization of a series of haloacetamide containing mechanism-based inactivators that are the most potent PAD inhibitors described to date.^{18,19}

The two most potent compounds, *N*- α -benzoyl-*N*⁵-(2-fluoro-1-iminoethyl)-*L*-ornithineamide (F-amidine; $k_{\text{inact}}/K_I = 3000 \text{ M}^{-1} \text{ min}^{-1}$)¹⁹ and *N*- α -benzoyl-*N*⁵-(2-chloro-1-iminoethyl)-*L*-ornithine




Figure 1. (A) PAD4 hydrolyzes peptidyl-arginine to form citrulline and ammonia. (B) Structure of haloacetamide-based inactivators of PAD4. (C) Two possible mechanisms of PAD4 inactivation.

* Corresponding author. Tel.: +1 803 777 6414; fax: +1 803 777 9521.

E-mail address: thompson@mail.chem.sc.edu (P. R. Thompson).

amide (Cl-amidine; $k_{\text{inact}}/K_I = 13,000 \text{ M}^{-1} \text{ min}^{-1}$),¹⁸ inactivate PAD4 by covalently modifying an active site cysteine (Cys645) that is involved in nucleophilic catalysis. Although the exact mechanism of inactivation has yet to be elucidated, it presumably proceeds through one of two routes (Fig. 1).

The initial syntheses of F- and Cl-amidine were carried out on the solid-phase (Rink AM amide resin) and proceeded in seven steps with an overall yield of 70% (Scheme 1).^{18,19} As with all solid-phase syntheses, this route was attractive because it mitigated the need to isolate intermediates by chromatography. In addition to serving as a solid support, the Rink resin also afforded the primary carboxamide upon acidic cleavage. While this method does generate the desired product in reasonable yield, there are considerable drawbacks, the most significant being the cost of the starting materials (~US\$950/g).


The major cost contributor is an orthogonally protected ornithine (Fmoc–Orn(Dde)–OH) that must be used in large excess (4-fold) to ensure quantitative coupling to the resin—this stoichiometry means a 75% loss from the outset. A second drawback of the solid-phase synthesis arises when the compound is cleaved from the resin. During this step, the acidic cleavage conditions inevitably result in some unintended hydrolysis of the primary amide. Not only does this reduce the overall yield but it necessitates the separation of the carboxylic acid and amide derivatives, which is tedious and time-consuming. If either F- or Cl-amidine are to become viable therapeutic candidates, a more practical synthesis is necessary; and as we moved forward to mouse trials, the need for a more cost effective method became clear. To this end, we have designed a solution-phase strategy to synthesize the more

potent of these compounds, that is, Cl-amidine in fewer steps, with higher yield, and at a significantly lower cost.


The solution-phase synthesis of Cl-amidine proceeded in four steps with an overall yield of 80% (Scheme 2). This route was particularly attractive because, similarly to the solid phase synthetic route, this procedure mitigates the need for time-consuming intermediate chromatography because all of the intermediates are isolated and purified by simple extractive work-ups.

The first challenge in this synthesis is differentiating between the two amino groups of ornithine. This challenge was easily met by choosing the mono-protected ornithine, H–Orn(Boc)–OH, a commodity chemical that is available at a considerably lower (~5-fold) cost than the ornithine derivative used previously. Benzoylation of the α -amine was accomplished with benzoyl chloride and afforded pure BzNH–Orn(Boc)–OH in 90% yield.²⁰ Next, we chose to convert the carboxylic acid into a primary amide. Using methodology developed by Nájera and co-workers²¹ conversion to the primary amide was achieved using the coupling reagent, HOTT, with ammonium chloride.²² In the final steps, the amidine moiety was installed on the δ -amine. Removal of the Boc-group with neat TFA proceeded in quantitative yield,²³ thus enabling the coupling of the free amine to ethyl chloroacetimidate hydrochloride in the presence of triethylamine.²⁴ This coupling procedure also proceeded quantitatively to afford the title compound in a total of four steps and 80% yield.

In conclusion, we have developed an efficient solution-phase synthesis of Cl-amidine. Using this method, the inactivator can be produced in fewer steps, with higher yields, and at a fraction of the previous cost (~US\$75/g).



Scheme 1. Reagents and conditions: (i) 20% piperidine, DMF; (ii) HBTU, HOBt, 0.4 M NMM, Fmoc–Orn(Dde)–OH, DMF; (iii) 20% piperidine, DMF; (iv) BzCl, 0.4 M NMM, DMF; (v) 2% hydrazine, DMF; (vi) ethyl chloroacetimidate (HCl), Et₃N, DMF; (vii) TFA/TIS/H₂O (95/2.5/2.5), 70%.



Scheme 2. Reagents and condition: (i) BzCl, NaOH, H₂O, 90%; (ii) HOTT, DIPEA, NH₄Cl, DMF, 89%; (iii) TFA, 100%; (iv) ethyl chloroacetimidate (HCl), 100%.

Acknowledgement

We thank the NIH (GM079357) for financial support.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2008.05.021.

References and notes

1. Moscarello, M. A.; Pritzker, L.; Mastronardi, F. G.; Wood, D. D. *J. Neurochem.* **2002**, *81*, 335–343.
2. Ishigami, A.; Ohsawa, T.; Hiratsuka, M.; Taguchi, H.; Kobayashi, S.; Saito, Y.; Murayama, S.; Asaga, H.; Toda, T.; Kimura, N.; Maruyama, N. *J. Neurosci. Res.* **2005**, *80*, 120–128.
3. Bhattacharya, S. K.; Crabb, J. S.; Bonilha, V. L.; Gu, X.; Takahara, H.; Crabb, J. W. *Invest. Ophthalmol. Vis. Sci.* **2006**, *47*, 2508–2514.
4. Bhattacharya, S. K.; Bhat, M. B.; Takahara, H. *Curr. Eye Res.* **2006**, *31*, 1063–1071.
5. Chang, X.; Han, J. *Mol. Carcinog.* **2006**, *45*, 183–196.
6. Vossenaar, E. R.; Van Venrooij, W. J. *Arthritis Res. Ther.* **2004**, *6*, 107–111.
7. Vossenaar, E. R.; Zendman, A. J.; van Venrooij, W. J.; Pruijn, G. J. *BioEssays* **2003**, *25*, 1106–1118.
8. Suzuki, A.; Yamada, R.; Chang, X.; Tokuhira, S.; Sawada, T.; Suzuki, M.; Nagasaki, M.; Nakayama-Hamada, M.; Kawaida, R.; Ono, M.; Ohtsuki, M.; Furukawa, H.; Yoshino, S.; Yukioka, M.; Tohma, S.; Matsubara, T.; Wakitani, S.; Teshima, R.; Nishioka, Y.; Sekine, A.; Iida, A.; Takahashi, A.; Tsunoda, T.; Nakamura, Y.; Yamamoto, K. *Nat. Genet.* **2003**, *34*, 395–402.
9. Kang, C. P.; Lee, H. S.; Ju, H.; Cho, H.; Kang, C.; Bae, S. C. *Arthritis Rheum.* **2006**, *54*, 90–96.
10. Lee, Y. H.; Rho, Y. H.; Choi, S. J.; Ji, J. D.; Song, G. G. *Rheumatol. Int.* **2007**, *27*, 827–833.
11. Plenge, R. M.; Padyukov, L.; Remmers, E. F.; Purcell, S.; Lee, A. T.; Karlson, E. W.; Wolfe, F.; Kastner, D. L.; Alfredsson, L.; Altshuler, D.; Gregersen, P. K.; Klareskog, L.; Rioux, J. D. *Am. J. Hum. Genet.* **2005**, *77*, 1044–1060.
12. Lundberg, K.; Nijenhuis, S.; Vossenaar, E. R.; Palmblad, K.; van Venrooij, W. J.; Klareskog, L.; Zendman, A. J.; Harris, H. E. *Arthritis Res. Ther.* **2005**, *7*, R458–R467.
13. Foulquier, C.; Sebbag, M.; Clavel, C.; Chapuy-Regaud, S.; Al Badine, R.; Mechin, M. C.; Vincent, C.; Nachat, R.; Yamada, M.; Takahara, H.; Simon, M.; Guerrin, M.; Serre, G. *Arthritis Rheum.* **2007**, *56*, 3541–3553.
14. Schellekens, G. A.; de Jong, B. A.; van den Hoogen, F. H.; van de Putte, L. B.; van Venrooij, W. J. *J. Clin. Invest.* **1998**, *101*, 273–281.
15. Schellekens, G. A.; Visser, H.; de Jong, B. A.; van den Hoogen, F. H.; Hazes, J. M.; Breedveld, F. C.; van Venrooij, W. J. *Arthritis Rheum.* **2000**, *43*, 155–163.
16. Machold, K. P.; Stamm, T. A.; Nell, V. P.; Pflugbeil, S.; Aletaha, D.; Steiner, G.; Uffmann, M.; Smolen, J. S. *Rheumatology (Oxford)* **2007**, *46*, 342–349.
17. Smolen, J. S.; Steiner, G. *Nat. Rev. Drug. Discov.* **2003**, *2*, 473–488.
18. Luo, Y.; Arita, K.; Bhatia, M.; Knuckley, B.; Lee, Y. H.; Stallcup, M. R.; Thompson, P. R. *Biochemistry* **2006**, *45*, 11727–11736.
19. Luo, Y.; Knuckley, B.; Lee, Y. H.; Stallcup, M. R.; Thompson, P. R. *J. Am. Chem. Soc.* **2006**, *128*, 1092–1093.
20. *Synthesis of N- α -benzoyl-N⁵-(tert-butoxycarbonyl)-l-ornithine*: N⁵-(tert-butoxycarbonyl)-l-ornithine (929 mg, 4.0 mmol) was dissolved in a biphasic mixture of aqueous NaOH (3.5 M, 1.16 mL, 4.0 mmol) and ether (4 mL). The mixture was cooled to 0 °C and alternating portions of benzoyl chloride (4.0 mmol, 0.464 mL) and aqueous NaOH (8.5 M, 4.0 mmol, 0.464 mL) were added every 5 min for 30 min. The reaction mixture was allowed to warm to rt and stirred overnight. The reaction was acidified (pH 1) with concd HCl and extracted with dichloromethane. The organics were combined, washed with brine, dried over MgSO₄, and concentrated to afford the product as a white powder (1.2 g, 90%). ¹H NMR (D₂O): δ 7.60 (d, 2H), 7.45–7.30 (m, 3H), 4.15 (m, 1H), 2.85 (m, 2H), 1.8–1.3 (m, 4H), 1.15 (s, 9H). ¹³C NMR (D₂O): δ 179.05, 170.34, 158.34, 133.65, 132.26, 128.87, 127.28, 80.90, 55.64, 39.83, 29.17, 27.80, 25.85. HRMS (C₁₇H₂₅N₂O₅⁺): calcd 337.1763, observed 337.1761.
21. Bailen, M. A.; Chinchilla, R.; Dodsworth, D. J.; Nájera, C. *Tetrahedron Lett.* **2000**, *41*, 2809–9813.
22. *Synthesis of N- α -benzoyl-N⁵-(tert-butoxycarbonyl)-l-ornithine amide*: N- α -Benzoyl-N⁵-(tert-butoxycarbonyl)-l-ornithine (420 mg, 1.24 mmol), HOTT (690 mg, 1.86 mmol), and DIPEA (0.44 mL, 2.5 mmol) were dissolved in DMF (5 mL). After stirring for 10 min, ammonium chloride (135 mg, 2.5 mmol) was added and stirring continued for 45 min. The reaction was partitioned between EtOAc (25 mL) and brine (60 mL). The layers were separated and the brine was extracted twice more with EtOAc. The organics were combined and washed with 2N HCl (2 \times 12 mL), water (2 \times 12 mL), saturated NaHCO₃ (2 \times 12), water (3 \times 12 mL), and brine (12 mL). The organics were then dried over MgSO₄ and concentrated to afford the product as a white powder (370 mg, 89%). ¹H NMR (DMSO-*d*₆): δ 8.28 (d, 1H), 7.85 (d, 2H), 7.6–7.4 (m, 3H), 7.35 (br s, 1H), 7.0 (br s, 1H), 6.78 (br s, 1H), 4.35 (m, 1H), 2.85 (m, 2H), 1.8–1.4 (m, 4H), 1.25 (s, 9H). ¹³C NMR (DMSO-*d*₆): δ 174.54, 167.0, 156.29, 134.89, 131.92, 128.84, 128.17, 78.1, 53.65, 29.72, 28.95, 27.1. HRMS (C₁₇H₂₆N₃O₄⁺): calcd 336.1923, observed 336.1927.
23. *Synthesis of N- α -benzoyl-l-ornithine amide*: N- α -Benzoyl-N⁵-(tert-butoxycarbonyl)-l-ornithine amide (220 mg, 0.66 mmol) was dissolved in cold TFA (6 mL) and stirred at 0 °C for 45 min. After warming to rt, the TFA was removed and the residue dissolved in water (5 mL) and washed with ether (5 mL) before being lyophilized. ¹H NMR (D₂O): δ 7.59 (m, 2H), 7.4–7.2 (m, 3H), 4.25 (m, 1H), 2.85 (m, 2H), 1.9–1.5 (m, 4H) ppm. ¹³C NMR (D₂O): δ 176.42, 171.06, 132.83, 132.63, 128.88, 127.40, 53.77, 38.99, 28.06, 23.59. HRMS (C₁₂H₁₈N₃O₂⁺): calcd 236.1399, observed 236.1397.
24. *Synthesis of Cl-amidine*: N- α -Benzoyl-l-ornithine amide-TFA (247 mg, 0.7 mmol) was dissolved in MeOH (2 mL). Triethyl amine (0.29 mL, 2.1 mmol) and ethyl chloroacetimidate-HCl (221 mg, 1.4 mmol) were added and the mixture stirred overnight. The reaction mixture was quenched with water (5 mL) and acidified with TFA. The product was isolated by RP-HPLC as a white powder. Spectral data were consistent with previous reports.